Search

Your search keyword '"Sindrup, Søren Hein"' showing total 155 results
Start Over Author "Sindrup, Søren Hein"
155 results on '"Sindrup, Søren Hein"'

2. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome

Author

Al-Hakem, Helle, Doets, Alex Y, Stino, Amro Maher, Zivkovic, Sasha A, Andersen, Henning, Willison, Hugh J, Cornblath, David R, Gorson, Kenneth C, Islam, Zhahirul, Mohammad, Quazi Deen, Sindrup, Søren Hein, Kusunoki, Susumu, Davidson, Amy, Casasnovas, Carlos, Bateman, Kathleen, Miller, James A L, van den Berg, Bianca, Verboon, Christine, Roodbol, Joyce, Leonhard, Sonja E, Arends, Samuel, Luijten, Linda W G, Benedetti, Luana, Kuwabara, Satoshi, Van den Bergh, Peter, Monges, Soledad, Marfia, Girolama A, Shahrizaila, Nortina, Galassi, Giuliana, Pereon, Yann, Bürmann, Jan, Kuitwaard, Krista, Kleyweg, Ruud P, Marchesoni, Cintia, Sedano Tous, María J, Querol, Luis, Martín-Aguilar, Lorena, Wang, Yuzhong, Nobile-Orazio, Eduardo, Rinaldi, Simon, Schenone, Angelo, Pardo, Julio, Vermeij, Frederique H, Waheed, Waqar, Lehmann, Helmar C, Granit, Volkan, Stein, Beth, Samijn, Johnny P A, van Dijk, Gert W, Jacobs, Bart C, Neurology, Medical Microbiology & Infectious Diseases, Public Health, and Immunology

Subjects
Neurology (clinical)
Abstract

BACKGROUND AND OBJECTIVES: To investigate CSF findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome (GBS) based on 1,500 patients in the International GBS Outcome Study. METHODS: Albuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (4 days 84%. High CSF protein levels were associated with a demyelinating subtype, proximal or global muscle weakness, and a reduced likelihood of being able to run at week 2 (odds ratio [OR] 0.42, 95% CI 0.25-0.70; p = 0.001) and week 4 (OR 0.44, 95% CI 0.27-0.72; p = 0.001). Patients with the Miller Fisher syndrome, distal predominant weakness, and normal or equivocal nerve conduction studies were more likely to have lower CSF protein levels. CSF cell count was

Published
2023

3. The effect of lacosamide in peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled, phenotype‐stratified trial

Author

Carmland, Malin Erika, primary, Kreutzfeldt, Melissa Dall, additional, Holbech, Jakob Vormstrup, additional, Brask‐Thomsen, Peter Kolind, additional, Krøigård, Thomas, additional, Hansen, Peter Nørregaard, additional, Tankisi, Hatice, additional, Jensen, Troels Staehelin, additional, Bach, Flemming Winther, additional, Sindrup, Søren Hein, additional, and Finnerup, Nanna Brix, additional

Published
2023
Full Text
View/download PDF

4. The effect of lacosamide in peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled, phenotype‐stratified trial.

Author

Carmland, Malin Erika, Kreutzfeldt, Melissa Dall, Holbech, Jakob Vormstrup, Brask‐Thomsen, Peter Kolind, Krøigård, Thomas, Hansen, Peter Nørregaard, Tankisi, Hatice, Jensen, Troels Staehelin, Bach, Flemming Winther, Sindrup, Søren Hein, and Finnerup, Nanna Brix

Abstract

Background: Neuropathic pain is common and difficult to treat. The sodium channel blocker lacosamide is efficacious in animal models of pain, but its effect on neuropathic pain in humans is inconclusive. Methods: In a multicentre, randomized, double‐blinded placebo‐controlled phenotype stratified trial, we examined if lacosamide produced better pain relief in patients with the irritable nociceptor phenotype compared to those without. The primary outcome was the change in daily average pain from baseline to last week of 12 weeks of treatment. Secondary and tertiary outcomes included pain relief, patient global impression of change and presence of 30% and 50% pain reduction. Results: The study was prematurely closed with 93 patients included and 63 randomized to lacosamide or placebo in a 2:1 ratio, of which 49 fulfilled the per protocol criteria and was used for the primary objective. We did not find a better effect of lacosamide in patients with the irritable nociceptor phenotype, the 95% CI for the primary objective was 0.41 (−1.2 to 2.0). For all patients randomized, lacosamide had no effect on the primary outcome, but significantly more patients were responders to lacosamide than during placebo, with an NNT of 4.0 (95% CI 2.3–16.1) and 5.0 (95% CI 2.8–24.5) for 30% and 50% pain reduction respectively. We did not identify any predictors for response. Lacosamide was generally well tolerated. Conclusion: We could not confirm that lacosamide was more efficacious in patients with the irritable nociceptor type, but the study was prematurely closed, so we cannot exclude a small difference. Significance: Treatment of neuropathic pain is often a trial and error process. Little is known about which patient benefit from which kind of medication. The sodium channel blocker lacosamide shows variable effect on neuropathic pain. Pain sensory phenotype, as defined by quantitative sensory testing, did not predict response to treatment with lacosamide. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes

Author

Gylfadottir, Sandra Sif, Christensen, Diana Hedevang, Nicolaisen, Sia Kromann, Andersen, Henning, Callaghan, Brian Christopher, Itani, Mustapha, Khan, Karolina Snopek, Kristensen, Alexander Gramm, Nielsen, Jens Steen, Sindrup, Søren Hein, Andersen, Niels Trolle, Jensen, Troels Staehelin, Thomsen, Reimar Wernich, and Finnerup, Nanna Brix

Published
2020
Full Text
View/download PDF

6. Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome

Author

Al-Hakem, Helle, primary, Doets, Alex Y, additional, Stino, Amro Maher, additional, Zivkovic, Sasha A., additional, Andersen, Henning, additional, Willison, Hugh J, additional, Cornblath, David R, additional, Gorson, Kenneth C, additional, Islam, Zhahirul, additional, Mohammad, Quazi Deen, additional, Sindrup, Søren Hein, additional, Kusunoki, Susumu, additional, Davidson, Amy, additional, Casasnovas, Carlos, additional, Bateman, Kathleen, additional, Miller, James AL, additional, van den Berg, Bianca, additional, Verboon, Christine, additional, Roodbol, Joyce, additional, Leonhard, Sonja E, additional, Arends, Samuel, additional, Luijten, Linda W G, additional, Benedetti, Luana, additional, Kuwabara, Satoshi, additional, Van den Bergh, Peter, additional, Monges, Soledad, additional, Marfia, Girolama A, additional, Shahrizaila, Nortina, additional, Galassi, Giuliana, additional, Pereon, Yann, additional, Bürmann, Jan, additional, Kuitwaard, Krista, additional, Kleyweg, Ruud P, additional, Marchesoni, Cintia, additional, Sedano Tous, María J, additional, Querol, Luis, additional, Martín-Aguilar, Lorena, additional, Wang, Yuzhong, additional, Nobile-Orazio, Eduardo, additional, Rinaldi, Simon, additional, Schenone, Angelo, additional, Pardo, Julio, additional, Vermeij, Frederique H, additional, Waheed, Waqar, additional, Lehmann, Helmar C, additional, Granit, Volkan, additional, Stein, Beth, additional, Cavaletti, Guido, additional, Gutiérrez-Gutiérrez, Gerardo, additional, Barroso, Fabio A, additional, Visser, Leo H, additional, Katzberg, Hans D, additional, Dardiotis, Efthimios, additional, Attarian, Shahram, additional, van der Kooi, Anneke J, additional, Eftimov, Filip, additional, Wirtz, Paul W, additional, PA Samijn, Johnny, additional, Gilhuis, H Jacobus, additional, DM Hadden, Robert, additional, Holt, James KL, additional, Sheikh, Kazim A, additional, Kolb, Noah, additional, Karafiath, Summer, additional, Vytopil, Michal, additional, Antonini, Giovanni, additional, Feasby, Thomas E, additional, Faber, Catharina, additional, Kramers, Hans, additional, Busby, Mark, additional, Roberts, Rhys C, additional, Silvestri, Nicholas J, additional, Fazio, Raffaella, additional, van Dijk, Gert W, additional, Garssen, Marcel PJ, additional, Verschuuren, Jan, additional, Harbo, Thomas, additional, and Jacobs, Bart C, additional

Published
2023
Full Text
View/download PDF

10. Comparison of diabetic and idiopathic sensory polyneuropathies with respect to nerve fibre affection and risk factors

Author

Itani, Mustapha, primary, Gylfadottir, Sif, additional, Krøigård, Thomas, additional, Gaist, Laura, additional, Holbech, Jakob Vormstrup, additional, Kristensen, Alexander Gramm, additional, Karlsson, Pall, additional, Möller, Sören, additional, Tankisi, Hatice, additional, Gaist, David, additional, Jensen, Troels S, additional, Finnerup, Nanna Brix, additional, and Sindrup, Søren Hein, additional

Published
2022
Full Text
View/download PDF

11. The characteristics of pain and dysesthesia in patients with diabetic polyneuropathy

Author

Gylfadottir, Sandra Sif, primary, Itani, Mustapha, additional, Kristensen, Alexander Gramm, additional, Karlsson, Pall, additional, Krøigård, Thomas, additional, Bennett, David L., additional, Tankisi, Hatice, additional, Andersen, Niels Trolle, additional, Jensen, Troels Staehelin, additional, Sindrup, Søren Hein, additional, and Finnerup, Nanna Brix, additional

Published
2022
Full Text
View/download PDF

13. Kronisk inflammatorisk demyeliniserende polyneuropati

Author

Markvardsen, Lars Kjøbsted, Harbo, Thomas, Holbech, Jakob Vormstrup, Tankisi, Hatice, Christiansen, Ingelise, Olsen, Niels Kjær, Jakobsen, Johannes, Sindrup, Søren Hein, and Andersen, Henning

Abstract

In this review, we discuss chronic inflammatory demyelinating polyneuropathy (CIDP), which is a disease with proximal and distal weakness and sensory disturbances resulting in impaired daily activity. The diagnosis is based on the clinical presentation and electrophysiology demonstrating demyelination in the peripheral nerves. CIDP can be successfully treated with immunoglobulin, glucocorticoids or plasma exchange, and during the latest decade, immunoglobulin has been administered subcutaneously improving patients’ flexibility and autonomy. By time, 30% of the patients will remit, and maintenance treatment will no longer be necessary.

Published
2020

14. Small and large fiber sensory polyneuropathy in type 2 diabetes: Influence of diagnostic criteria on neuropathy subtypes

Author

Itani, Mustapha, primary, Gylfadottir, Sandra Sif, additional, Krøigård, Thomas, additional, Kristensen, Alexander Gramm, additional, Christensen, Diana Hedevang, additional, Karlsson, Pall, additional, Möller, Sören, additional, Andersen, Henning, additional, Tankisi, Hatice, additional, Nielsen, Jens Steen, additional, Jensen, Troels Staehelin, additional, Thomsen, Reimar Wernich, additional, Finnerup, Nanna Brix, additional, and Sindrup, Søren Hein, additional

Published
2020
Full Text
View/download PDF

15. An International Perspective on Preceding Infections in Guillain-Barré Syndrome

Author

Leonhard, Sonja E., van der Eijk, Annemiek A., Andersen, Henning, Antonini, Giovanni, Arends, Samuel, Attarian, Shahram, Barroso, Fabio A., Bateman, Kathleen J., Batstra, Manou R., Benedetti, Luana, van den Berg, Bianca, Van den Bergh, Peter, Bürmann, Jan, Busby, Mark, Casasnovas, Carlos, Cornblath, David R., Davidson, Amy, Doets, Alex Y., van Doorn, Pieter A., Dornonville de la Cour, Charlotte, Feasby, Thomas E., Fehmi, Janev, Garcia-Sobrino, Tania, Goldstein, Jonathan M., Gorson, Kenneth C., Granit, Volkan, Hadden, Robert D.M., Harbo, Thomas, Hartung, Hans-Peter, Hasan, Imran, Holbech, Jakob V., Holt, James K.L., Jahan, Israt, Islam, Zhahirul, Karafiath, Summer, Katzberg, Hans D., Kleyweg, Ruud P., Kolb, Noah, Kuitwaard, Krista, Kuwahara, Motoi, Kusunoki, Susumu, Luijten, Linda W.G., Kuwabara, Satoshi, Lee Pan, Edward, Lehmann, Helmar C., Maas, Marijke, Martín-Aguilar, Lorena, Miller, James A.L., Mohammad, Quazi Deen, Monges, Soledad, Nedkova-Hristova, Velina, Nobile-Orazio, Eduardo, Pardo, Julio, Pereon, Yann, Querol, Luis, Reisin, Ricardo, Van Rijs, Wouter, Rinaldi, Simon, Roberts, Rhys C., Roodbol, Joyce, Shahrizaila, Nortina, Sindrup, Søren Hein, Stein, Beth, Cheng-Yin, Tan, Tankisi, Hatice, Tio-Gillen, Anne P., Sedano Tous, María J., Verboon, Christine, Vermeij, Frederique H., Visser, Leo H., Huizinga, Ruth, Willison, Hugh J., and Jacobs, Bart C.

Published
2022
Full Text
View/download PDF

17. Antibodies in patients with chronic inflammatory demyelinating polyneuropathy

Author

Momamed, Abdullahi Ahmed, Krøigård, Thomas, Agerbo Gaist, Thomas, Markvardsen, Lars Kjøbsted, Sindrup, Søren Hein, Andersen, Henning, and Blaabjerg, Morten

Abstract

Recent studies have identified specific immunoglobulin (Ig) G4 antibodies against the paranodal proteins neurofascin 155 and contactin 1 in subgroups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These patients present with distinct clinical phenotypes and poor response to first-line therapy with intravenous Ig. Detection of these antibodies in patients with CIDP has diagnostic, prognostic, and therapeutic implications. This review summarises the current knowledge on clinical characteristics, pathogenesis and treatment of these patients.

Published
2019

18. Guillain-Barré syndrome in Denmark:Validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period

Author

Levison, Lotte Sahin, Thomsen, Reimar Wernich, Christensen, Diana Hedevang, Mellemkjær, Thomas, Sindrup, Søren Hein, and Andersen, Henning

Subjects
PUBLIC-HEALTH SURVEILLANCE, Positive predictive value, HOSPITAL DISCHARGE DATA, Epidemiology, International classification of disease codes, EPIDEMIOLOGIC ANALYSIS, UNITED-STATES, QUALITY, registries
Abstract

Purpose: To validate the diagnostic codes for Guillain-Barré syndrome (GBS) in the Danish National Patient Registry (DNPR). Secondly, to examine 30-year trends in the incidence of GBS in Denmark. Patients and methods: We used the DNPR to identify all patients aged 16 and above diagnosed with a primary GBS diagnosis at any Danish department of neurology between 1987 and 2016. Medical files were reviewed according to the clinical criteria of the National Institute of Neurological Disorders and Stroke Committee and classified according to the Brighton criteria. The incidence rate (IR) was calculated based on data from 1987 to 2016 and stratified by season, gender, and age. Results: Over 30 years, we identified 2,319 patients aged 16 and above in the DNPR. From a validation cohort of 573 patients, we were able to retrieve 425 (74.2%) medical files; 356 GBS diagnoses were confirmed. The overall positive predictive value was 83.8% (95% confidence interval (CI): 80.0-87.0). In 99% of the confirmed patients, the Brighton criteria level 1-3 for GBS were met. The IR was fairly stable over 30 years at 1.77 per 100,000 person years (95% CI: 1.70-1.84). The incidence was higher in the winter season (IR ratio compared with summer: 1.18 (95% CI: 1.09-1.29)), and was strongly associated with male gender (IR ratio vs females: 1.44 (95% CI: 1.33-1.57)). IRs rose with age at diagnosis, particularly after the age of 50 in both men and women and a minor peak was observed for total IR in young adults. Conclusion: Primary diagnostic codes for GBS at Danish departments of neurology have high validity. The DNPR is a well-suited data source for epidemiological research on GBS. The Danish nationwide 30-year GBS IR is stable over time and similar to GBS IRs reported in other European and North American populations.

Published
2019

25. Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes

Author

Gylfadottir, Sandra Sif, primary, Christensen, Diana Hedevang, additional, Nicolaisen, Sia Kromann, additional, Andersen, Henning, additional, Callaghan, Brian Christopher, additional, Itani, Mustapha, additional, Khan, Karolina Snopek, additional, Kristensen, Alexander Gramm, additional, Nielsen, Jens Steen, additional, Sindrup, Søren Hein, additional, Andersen, Niels Trolle, additional, Jensen, Troels Staehelin, additional, Thomsen, Reimar Wernich, additional, and Finnerup, Nanna Brix, additional

Published
2019
Full Text
View/download PDF

28. Small and large fiber sensory polyneuropathy in type 2 diabetes: Influence of diagnostic criteria on neuropathy subtypes.

Author

Itani, Mustapha, Gylfadottir, Sandra Sif, Krøigård, Thomas, Kristensen, Alexander Gramm, Christensen, Diana Hedevang, Karlsson, Pall, Möller, Sören, Andersen, Henning, Tankisi, Hatice, Nielsen, Jens Steen, Jensen, Troels Staehelin, Thomsen, Reimar Wernich, Finnerup, Nanna Brix, and Sindrup, Søren Hein

Subjects
NEURONS, DIABETIC neuropathies, MATHEMATICAL models, TYPE 2 diabetes, POLYNEUROPATHIES, THEORY, DESCRIPTIVE statistics, STATISTICAL correlation, DISEASE complications
Abstract

Diabetic polyneuropathy (DPN) can be classified based on fiber diameter into three subtypes: small fiber neuropathy (SFN), large fiber neuropathy (LFN), and mixed fiber neuropathy (MFN). We examined the effect of different diagnostic models on the frequency of polyneuropathy subtypes in type 2 diabetes patients with DPN. This study was based on patients from the Danish Center for Strategic Research in Type 2 Diabetes cohort. We defined DPN as probable or definite DPN according to the Toronto Consensus Criteria. DPN was then subtyped according to four distinct diagnostic models. A total of 277 diabetes patients (214 with DPN and 63 with no DPN) were included in the study. We found a considerable variation in polyneuropathy subtypes by applying different diagnostic models independent of the degree of certainty of DPN diagnosis. For probable and definite DPN, the frequency of subtypes across diagnostic models varied from: 1.4% to 13.1% for SFN, 9.3% to 21.5% for LFN, 51.4% to 83.2% for MFN, and 0.5% to 14.5% for non‐classifiable neuropathy (NCN). For the definite DPN group, the frequency of subtypes varied from: 1.6% to 13.5% for SFN, 5.6% to 20.6% for LFN, 61.9% to 89.7% for MFN, and 0.0% to 6.3% for NCN. The frequency of polyneuropathy subtypes depends on the type and number of criteria applied in a diagnostic model. Future consensus criteria should clearly define sensory functions to be tested, methods of testing, and how findings should be interpreted for both clinical practice and research purpose. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

30. Statins and polyneuropathy revisited:Case-control study in Denmark, 1999-2013

Author

Svendsen, Toke de Koning, Hansen, Peter Nørregaard, García-Rodríguez, Luis Alberto, Andersen, Lene, Hallas, Jesper, Sindrup, Søren Hein, and Gaist, David

Subjects
Male, Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects, case-control study, statin, Middle Aged, Polyneuropathies/chemically induced, Denmark/epidemiology, Case-Control Studies, Journal Article, adverse effects, risk factors, Humans, epidemiology, Female, polyneuropathy, Registries, Aged
Abstract

Aim: In a previous study, we found a positive association between statin use and polyneuropathy risk. Other studies reported equivocal results. The present study aimed to confirm our findings with a design similar to that used in our previous study but with a larger data set. Methods: We searched medical registry data to identify patients diagnosed with incident polyneuropathy of no known cause (idiopathic polyneuropathy) between 1999 and 2013; we verified diagnoses through medical records. For each case, we recruited 20 general population controls with no previous history of polyneuropathy. Controls were matched to their respective case for age and gender. We ascertained the prior statin use of cases and controls through a prescription registry. Based on this information, exposure to statins was categorized into ‘ever use’ or ‘never use’. Ever use of statins was classified by how recently they had been used (‘current use’ or ‘past use’); current use was further classified into long-term use (5+ years) and high- or low-intensity use. We used conditional logistic regression to calculate odds ratios (ORs) with 95% confidence intervals (CIs) to examine associations between polyneuropathy and statin use. Results: We included 370 validated cases and 7400 controls. Ever use of statins was not associated with an elevated risk of polyneuropathy (OR 1.14, 95% CI 0.84, 1.54). Similarly, we found no associations between polyneuropathy risk and current use (OR 1.11, 95% CI 0.79, 1.53), long-term use (OR 1.13, 95% CI 0.66, 1.92) or high-intensity statin use (OR 1.05, 95% CI 0.59, 1.84). Conclusion: Statin use was not associated with an increased risk of idiopathic polyneuropathy.

Published
2017

32. Statin use and peripheral nerve function—A prospective follow‐up study.

Author

Svendsen, Toke de Koning, Krøigård, Thomas, Wirenfeldt, Martin, Schrøder, Henrik Daa, Bak, Søren, Möller, Sören, Hallas, Jesper, Sindrup, Søren Hein, and Gaist, David

Subjects
PERIPHERAL nervous system, LONGITUDINAL method, PERIPHERAL neuropathy, NEURAL conduction, SYMPTOMS, SKIN biopsy
Abstract

Purpose: To examine the association between use of statins and risk of deterioration of peripheral nerve function. Methods: We prospectively followed patients who initiated statin treatment and compared them with statin never‐users (non‐users). At the time of inclusion and at 1‐year follow‐up, participants underwent tests for peripheral nerve function (ie nerve conduction studies, quantitative sensory testing), skin biopsies and ratings of symptoms and signs of neuropathy. We selected five tests of nerve function and the intraepidermal nerve fibre density (IENFD) a priori as primary outcomes. We used linear regression to test for differences between statin users and non‐users with Holm‐Bonferroni‐corrected statistical significance level of.05. Results: Comparisons were based on 57 statin users and 46 non‐users. Changes in nerve function test results during follow‐up were not uniform with regard to direction and were statistically not significant with the exception of IENFD (change in IENFD: statin users 1 fibre/mm vs. non‐statin users −2 fibres/mm; P‐value =.006). None of the participants developed overt peripheral neuropathy. However, five statin users developed neuropathy‐like symptoms and a post hoc analysis showed a significant decrease in vibration sensitivity compared to asymptomatic statin users. Conclusion: Statin use was not clearly associated with increased risk of deterioration of peripheral nerve function analysed at a group level. However, given the sample size limitations of our study and the findings of our post hoc analysis, we cannot preclude that peripheral nerve function may be affected in some individuals exposed to statins. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

33. Statins and polyneuropathy revisited

Author

Svendsen, Toke de Koning, Nørgaard Hansen, Peter, Rodríguez, Luis Alberto García, Andersen, Lene, Hallas, Jesper, Sindrup, Søren Hein, and Gaist, David

Published
2016

34. Patient med nedsat leverfunktion fik myoklonier under behandling med selektive serotoningenoptagelseshæmmere

Author

Forsberg-Gillving, Mimmi, Bode, Matthias, and Sindrup, Søren Hein

Subjects
digestive, oral, and skin physiology, mental disorders, behavioral disciplines and activities, nervous system diseases
Abstract

Side effects such as myoclonus and tremor are rare when treating with selective serotonin reuptake inhibitors (SSRIs). We present a case where a patient with known liver cirrho-sis and in treatment with citalopram developed myoclonus, tremor and gait difficulties. The symptoms were reduced when the SSRI dose was decreased. In patients with unexplained movement disorders the usage of SSRIs should be considered as a cause. Furthermore, treatment with SSRIs should be carefully assessed in patients with reduced liver function.

Published
2015

38. Analgetika

Author

Nikolajsen, Lone, Finnerup, Nanna Brix, Sindrup, Søren Hein, Jensen, Troels Staehelin, Dahl, Jørgen Berg, and Arendt-Nielsen, Lars

Published
2013

42. Monoklonal gammopati af ukendt signifikans kan medføre polyneuropati og oftalmoplegi

Author

Kolmos, Eva Brøsted, Moth Henriksen, Marie, Abildgaard, Niels, and Sindrup, Søren Hein

Subjects
genetic structures, eye diseases
Abstract

CANOMAD is a rare syndrome of chronic ataxic polyneuropathy, ophtalmoplegia, IgM paraprotein, cold agglutinins and anti-disialosyl antibodies. We present a case of a 65-year-old woman with clinical and electrophysiological features of chronic sensory polyneuropathy and diplopia. Serum samples from the patient contained IgM paraprotein and anti-GM2-antibodies. Treatment with intravenous immunoglobulins resulted in an improvement of the patient's diplopia and polyneuropathy. The case shows the importance of considering CANOMAD as a cause of diplopia in patients with chronic sensory polyneuropathy.

Published
2012

45. Polyneuropati:Farmakologisk behandling af smerter

Author

Sindrup, Søren Hein and Gaist, David

Subjects
Polyneuropathies, treatment, behandling, Neuropatiske smerte, Neuropathic pain, Polyneuropatier
Abstract

Udgivelsesdato: April

Published
2009

46. Polyneuropati:Udredning og klassifikation

Author

Gaist, David and Sindrup, Søren Hein

Subjects
Polyneuropathies, classification, Polyneuropatier, klassifikation
Abstract

Udgivelsesdato: Marts

Published
2009

47. Sekundære analgetika

Author

Sindrup, Søren Hein, Finnerup, Nanna Brix, Jensen, Troels Staehelin, Dahl, Jørgen B., and Arendt-Nielsen, Lars

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results